Coronavirus disease 2019 vaccination and infertility treatment outcomes.
COVID-19
infertility treatments
mRNA vaccine
Journal
Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
12
08
2021
revised:
22
02
2022
accepted:
22
02
2022
pubmed:
20
4
2022
medline:
31
5
2022
entrez:
19
4
2022
Statut:
ppublish
Résumé
To assess the influence of coronavirus disease 2019 (COVID-19) messenger ribonucleic acid vaccine on ovarian response and in vitro fertilization (IVF) treatment outcomes. A retrospective cohort study. A tertiary university-affiliated medical center and a private medical center. The study included a total of 400 patients, 200 vaccinated women and 200 age-matched unvaccinated women, who underwent IVF in January-April 2021. None. The mean number of oocytes retrieved and clinical pregnancy rates in vaccinated vs. unvaccinated patients. A total of 200 patients underwent oocyte retrieval 14-68 days after receiving COVID-19 vaccination. No difference was found in the mean number of oocytes retrieved per cycle (10.63 vs. 10.72) between vaccinated and unvaccinated patients. Among 128 vaccinated and 133 unvaccinated patients who underwent fresh embryos transfers, no difference was demonstrated in the clinical pregnancy rates (32.8% vs. 33.1%), with 42 and 44 clinical pregnancies, respectively. The fertilization rates and mean number of cryopreserved embryos were similar between the 2 groups in freeze-all cycles (55.43% vs. 54.29% and 3.59 vs. 3.28, respectively). Among vaccinated and unvaccinated patients who underwent fresh embryo transfers, no difference was noted in the fertilization rate (64.81% vs. 61.98%) and transferred embryos' quality. Regression models applied demonstrated no effect of the vaccine on oocyte yields and pregnancy rates. The COVID-19 messenger ribonucleic acid vaccine did not affect the ovarian response or pregnancy rates in IVF treatment. Women should be vaccinated for COVID-19 before attempting to conceive via IVF treatments, given the higher risk of severe illness in pregnant women.
Identifiants
pubmed: 35437147
pii: S0015-0282(22)00144-3
doi: 10.1016/j.fertnstert.2022.02.025
pmc: PMC8872833
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1291-1299Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Références
Hum Reprod Update. 2014 May-Jun;20(3):370-85
pubmed: 24430863
Hum Reprod. 2022 Mar 1;37(3):534-541
pubmed: 34935913
Reprod Biol Endocrinol. 2021 May 13;19(1):69
pubmed: 33985514
Vaccine. 2021 Apr 8;39(15):2024-2034
pubmed: 33722411
Hum Reprod. 2020 Dec 1;35(12):2774-2783
pubmed: 32877507
J Matern Fetal Neonatal Med. 2022 Jun;35(12):2420-2421
pubmed: 32510261
Am J Epidemiol. 2022 Jan 20;:
pubmed: 35051292
Fertil Steril. 2021 Jul;116(1):16-24
pubmed: 34148583
Physiol Rev. 2021 Jan 1;101(1):303-318
pubmed: 32969772
J Ovarian Res. 2015 Nov 04;8:69
pubmed: 26536862
Biology (Basel). 2021 Mar 19;10(3):
pubmed: 33808658
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
JAMA. 2021 Jul 20;326(3):273-274
pubmed: 34137808
Reprod Biomed Online. 2020 Jul;41(1):89-95
pubmed: 32466994
Hum Reprod. 2021 Aug 18;36(9):2506-2513
pubmed: 34364311
Andrology. 2021 Jul;9(4):1027-1037
pubmed: 33427404
JAMA. 2021 Aug 24;326(8):728-735
pubmed: 34251417
Hum Reprod. 2011 Jun;26(6):1270-83
pubmed: 21502182